HiberCell
Kathryn Bieging-Rolett, PhD has worked in a variety of scientific roles since 2004. Kathryn began their career as an Emerging Infectious Diseases Training Fellow at the Centers for Disease Control in 2004. In 2005, they became a Graduate Student at Northwestern University. From 2010 to 2015, they were a Postdoctoral Fellow at Stanford University School of Medicine. Kathryn then worked as a Basic Life Science Research Associate at Stanford University School of Medicine from 2015 to 2021. Currently, they are a Scientist II at HiberCell.
Kathryn Bieging-Rolett, PhD, obtained their PhD in Viral Oncogenesis from Northwestern University - The Feinberg School of Medicine in 2010. Prior to that, they earned their BA in Biology from Macalester College in 2004.
This person is not in any offices
HiberCell
2 followers
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” they are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy.